Developing a new dry powder aerosol to help patients with severe breathing problems
Preclinical development of a synthetic lung surfactant dry powder aerosol for hypoxemia or acute respiratory distress syndrome patients receiving different modes of ventilation support
This study is testing a new dry powder treatment that can be turned into a mist to help people with breathing problems like hypoxemia or ARDS, and it aims to see if this treatment can reduce lung inflammation and work even better when combined with another medicine.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Virginia Commonwealth University NIH-funded |
| Lab location | 1 site (Richmond, United States) |
| Project ID | NIH-11020319 on NIH RePORTER |
What this research studies
This research focuses on creating a synthetic lung surfactant in dry powder form that can be delivered as an aerosol to patients suffering from hypoxemia or acute respiratory distress syndrome (ARDS). The project involves preclinical testing using a rat model to evaluate the effectiveness of this new treatment in reducing lung inflammation caused by mechanical ventilation. The research also explores the potential of combining this surfactant with a small molecule inhibitor to enhance its therapeutic effects. By investigating these approaches, the research aims to improve respiratory support for patients in critical care settings.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults experiencing hypoxemia or ARDS who require mechanical ventilation support.
Not a fit: Patients with chronic respiratory conditions or those not requiring ventilatory support may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a novel treatment that significantly improves oxygenation and reduces lung injury in patients with severe respiratory conditions.
How similar studies have performed: Previous research has shown promise in using aerosolized surfactants for respiratory conditions, indicating potential for success with this novel approach.
Where this research is happening
Richmond, United States
- Virginia Commonwealth University — Richmond, United States (Active)
Researchers
- Principal investigator: Longest, P. Worth — Virginia Commonwealth University
- Study coordinator: Longest, P. Worth
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.